Sirtex unveils first-of-its-kind product to treat peripheral vascular hemorrhage

Sirtex推出首款治疗周围血管出血的产品

WOBURN, Mass., Oct. 27, 2023 /PRNewswire/ -- Sirtex Medical ('Sirtex'), a leading manufacturer of interventional treatment solutions, announced today the commercial availability of the LAVA® Liquid Embolic System, the first and only liquid embolic approved for the treatment of peripheral vascular hemorrhage..

马萨诸塞州沃本市，2023年10月27日/PRNewswire/-Sirtex Medical（'Sirtex'）是介入治疗解决方案的领先制造商，今天宣布LAVA®液体栓塞系统的商业可用性，这是第一个也是唯一的液体栓塞被批准用于治疗外周血管出血。。

LAVA® provides volume and viscosity options that optimize the flexibility needed to treat patients with controlled target vessel occlusion. The product's 2mL and 6mL options are optimized for the peripheral vasculature, and its viscosity options allow for the distal embolization of small vessels that may be inaccessible via other embolics..

LAVA®提供体积和粘度选项，优化治疗受控靶血管闭塞患者所需的灵活性。该产品的2mL和6mL选项针对周围脉管系统进行了优化，其粘度选项允许通过其他栓塞无法进入的小血管远端栓塞。。

'This product's ability to maximize the packing density within the target vessel is incredibly important, as it allows us to minimize the likelihood of a future recurrence or restoration of vessel patency,' said Dr. Gary Siskin, Professor and Chairman of the Department of Radiology at Albany Medical Center..

“该产品最大限度地提高目标血管内包装密度的能力非常重要，因为它使我们能够最大限度地减少未来复发或恢复血管通畅的可能性，”奥尔巴尼医疗中心放射科教授兼主席加里西斯金博士说。。

In a study of the LAVA® Liquid Embolic System for the embolic treatment of arterial hemorrhage in peripheral vasculature, the product met both the primary safety and effectiveness endpoints, with 100% of patients experiencing no major adverse events in 30 days and 94% of lesions meeting clinical success in 30 days..

在一项用于栓塞治疗外周血管动脉出血的LAVA®液体栓塞系统的研究中，该产品符合主要安全性和有效性终点，100%的患者在30天内没有发生重大不良事件，94%的患者在30天内达到临床成功。。

'The trial was an incredible success. Our goal was to achieve 70% efficacy for the existing data and outcomes, but we were able to achieve 94% efficacy,' said Dr. Bulent Arslan, Professor of the Division of Interventional Radiology and Director of Vascular and Interventional Radiology at RUSH Medical College.

'审判是一个令人难以置信的成功。我们的目标是对现有数据和结果达到70%的疗效，但我们能够达到94%的疗效，“RUSH医学院介入放射科教授，血管和介入放射科主任Bulent Arslan博士说。学院。

'I'm overjoyed that it's now available for all of our patients.'.

“我非常高兴它现在适用于我们所有的病人。”。

'The approval and availability of LAVA® is especially meaningful to our team because it is addressing previously unmet needs in vascular medicine, with the potential to create significant impact on patients' lives,' said Matt Schmidt, Chief Commercial Officer of Sirtex. 'We are delighted to expand our Sirtex product portfolio with this treatment milestone that directly furthers our mission to improve the quality and longevity of patient lives through innovative medical solutions, and we thank everyone who played a role to achieve it.'.

Sirtex首席商务官Matt Schmidt说：“LAVA®的批准和可用性对我们的团队特别有意义，因为它正在解决以前未满足的血管医学需求，并有可能对患者的生活产生重大影响。”我们很高兴通过这一治疗里程碑扩展我们的Sirtex产品组合，直接推动我们通过创新医疗解决方案改善患者生活质量和寿命的使命，并感谢为实现这一目标而发挥作用的所有人。

About SirtexSirtex is a global healthcare business with offices in the U.S., Australia, Europe and Asia, working to improve outcomes in people with cancer. Sirtex's current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres® Y-90 resin microspheres. For more information, visit www.sirtex.com..

关于SirtexSirtex是一家在美国，澳大利亚，欧洲和亚洲设有办事处的全球医疗保健业务，致力于改善癌症患者的预后。Sirtex目前的主要产品是针对肝癌的靶向放射疗法，称为SIRSpheres®Y-90树脂微球。欲了解更多信息，请访问www.sirtex.com。。

APM-GL-001-09-23

APM-GL-001-09-23

SOURCE Sirtex

源Sirtex